TSHA
Taysha Gene TherapiesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
TSHA vs peer average
48/100
TSHA vs. peer average (D vs. D)
Grade spread
B 1 · C 2 · D 4 · F 3
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
ACAD is the first available peer comparator.
Rett-syndrome commercial comparator, not a gene-therapy development peer: Acadia markets trofinetide. Its product and commercial maturity limit valuation comparability. https://ir.acadia.com/news/news-details/2026/European-Commission-Approves-DAYBU-trofinetide-as-the-First-and-Only-Treatment-for-Neurobehavioral-Symptoms-of-Rett-Syndrome-in-the-European-Union/default.aspx
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
TSHA
Taysha Gene Therapies
ACAD
ACADIA
Grade
D
D
Momentum
7
7
Value
41
62
Sentiment
58
44
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Defensive
Grade position vs ACAD
TSHA / ACAD
Grade Position
In line
TSHA vs. peer average (D vs. D)
48/100
Momentum
7
TSHAValue
41
ACADSentiment
58
TSHARotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs TSHA
ACAD is the first peer returned for this comparison set.